Skip to main content

Jorden David Emerson's Form 4 filing

Nuo Therapeutics, Inc. (AURX) · filed Nov 14, 2022

Accession no.
0001437749-22-027386
Filed
Nov 14, 2022
Trade date
Nov 9, 2022
Filing delay
5 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 9 non-derivative transactions and 0 derivative transactions. Open-market sales total $243.8K. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Jorden David EmersonCIK 0001313516Director, Officer (CEO/CFO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 9, 2022Common StockSSaleDisposed−30,000$1.50−$45,0002,107,858Direct
Nov 9, 2022Common StockSSaleDisposed−30,000$1.50−$45,0002,077,858Direct
Nov 9, 2022Common StockSSaleDisposed−27,000$1.50−$40,5002,050,858Direct
Nov 9, 2022Common StockSSaleDisposed−20,000$1.50−$30,0002,030,858Direct
Nov 9, 2022Common StockSSaleDisposed−20,000$1.50−$30,0002,010,858Direct
Nov 9, 2022Common StockSSaleDisposed−13,500$1.50−$20,2501,997,358Direct
Nov 9, 2022Common StockSSaleDisposed−10,000$1.50−$15,0001,987,358Direct
Nov 9, 2022Common StockSSaleDisposed−7,000$1.50−$10,5001,980,358Direct
Nov 9, 2022Common StockSSaleDisposed−5,000$1.50−$7,5001,975,358Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)